Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir + F/TAF vs Dolutegravir + F/TAF in Treatment-Naive HIV-1
NCT02397694Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bictegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Mar 2015; status: completed.
02
Drugs
bictegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02397694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397694.